Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Mol Neurodegener ; 15(1): 39, 2020 07 16.
Artigo em Inglês | MEDLINE | ID: mdl-32677995

RESUMO

Tau aggregation into amyloid fibers based on the cross-beta structure is a hallmark of several Tauopathies, including Alzheimer Disease (AD). Trans-cellular propagation of Tau with pathological conformation has been suggested as a key disease mechanism. This is thought to cause the spreading of Tau pathology in AD by templated conversion of naive Tau in recipient cells into a pathological state, followed by assembly of pathological Tau fibers, similar to the mechanism of nucleated polymerization proposed for prion pathogenesis. In cell cultures, the process is often monitored by a FRET assay where the recipient cell expresses the Tau repeat domain (TauRD) with a pro-aggregant mutation, fused to GFP-based FRET pairs. Since the size of the reporter GFP (barrel of ~ 3 nm × 4 nm) is ~ 7 times larger than the ß-strand distance (0.47 nm), this points to a potential steric clash. Hence, we investigated the influence of the GFP tag on TauFL or TauRD aggregation. Using biophysical methods (light scattering, atomic force microscopy (AFM), and scanning-transmission electron microscopy (STEM)), we found that the assembly of TauRD-GFP was severely inhibited and incompatible with that of Alzheimer filaments. These observations argue against the hypothesis that the propagation of Tau pathology in AD is caused by the prion-like templated aggregation of Tau protein, transmitted via cell-to-cell spreading of Tau. Thus, even though the observed local increase of FRET in recipient cells may be a valid hallmark of a pathological reaction, our data argue that it is caused by a process distinct from assembly of TauRD filaments.


Assuntos
Doença de Alzheimer/metabolismo , Encéfalo/metabolismo , Transferência Ressonante de Energia de Fluorescência , Tauopatias/metabolismo , Proteínas tau/metabolismo , Doença de Alzheimer/genética , Animais , Modelos Animais de Doenças , Transferência Ressonante de Energia de Fluorescência/métodos , Humanos , Mutação/genética , Príons/genética , Príons/metabolismo
2.
Neurobiol Aging ; 57: 47-63, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28600952

RESUMO

The aggregation of Tau protein is a hallmark of neurodegenerative diseases including Alzheimer's disease. Previously, we generated a cell model of tauopathy based on the 4-repeat domain with the FTDP-17 mutation ΔK280 (Tau4RDΔK) which is expressed in a regulatable fashion (tet-on). The deletion variant ΔK280 is highly amyloidogenic and forms fibrous aggregates in neuroblastoma N2a cells staining with the reporter dye Thioflavin S. The aggregation of Tau4RDΔK is toxic, contrary to wildtype or anti-aggregant variants of the protein. Using a novel approach for monitoring in situ Tau aggregation and toxicity by combination of microscopic analysis with FACS and biochemical analysis of cells enabled the dissection of the aggregating species which cause a time-dependent increase of toxicity. The dominant initiating step is the dimerization of Tau4RDΔK which leads to further aggregation and induces a strong increase in reactive oxygen species (ROS) and cytoplasmic Ca2+ which damage the membranes and cause cell death. Tau-based treatments using Tau aggregation inhibitors reduce both soluble oligomeric and fully aggregated Tau species and decrease their toxicity.


Assuntos
Hidrazinas/farmacologia , Hidrazinas/uso terapêutico , Tauopatias/prevenção & controle , Tiazóis/farmacologia , Tiazóis/uso terapêutico , Proteínas tau/metabolismo , Proteínas tau/toxicidade , Cálcio/metabolismo , Morte Celular , Células Cultivadas , Citoplasma/metabolismo , Dimerização , Relação Dose-Resposta a Droga , Mutação , Agregados Proteicos , Espécies Reativas de Oxigênio/metabolismo , Fatores de Tempo
3.
J Biol Chem ; 289(49): 34389-407, 2014 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-25339173

RESUMO

Abnormal phosphorylation ("hyperphosphorylation") and aggregation of Tau protein are hallmarks of Alzheimer disease and other tauopathies, but their causative connection is still a matter of debate. Tau with Alzheimer-like phosphorylation is also present in hibernating animals, mitosis, or during embryonic development, without leading to pathophysiology or neurodegeneration. Thus, the role of phosphorylation and the distinction between physiological and pathological phosphorylation needs to be further refined. So far, the systematic investigation of highly phosphorylated Tau was difficult because a reliable method of preparing reproducible quantities was not available. Here, we generated full-length Tau (2N4R) in Sf9 cells in a well defined phosphorylation state containing up to ∼20 phosphates as judged by mass spectrometry and Western blotting with phospho-specific antibodies. Despite the high concentration in living Sf9 cells (estimated ∼230 µm) and high phosphorylation, the protein was not aggregated. However, after purification, the highly phosphorylated protein readily formed oligomers, whereas fibrils were observed only rarely. Exposure of mature primary neuronal cultures to oligomeric phospho-Tau caused reduction of spine density on dendrites but did not change the overall cell viability.


Assuntos
Córtex Cerebral/metabolismo , Hipocampo/metabolismo , Neurônios/metabolismo , Multimerização Proteica/genética , Processamento de Proteína Pós-Traducional , Sequência de Aminoácidos , Animais , Anticorpos Fosfo-Específicos/química , Baculoviridae/genética , Córtex Cerebral/citologia , Córtex Cerebral/efeitos dos fármacos , Expressão Gênica , Hipocampo/citologia , Hipocampo/efeitos dos fármacos , Humanos , Camundongos , Dados de Sequência Molecular , Neurônios/citologia , Neurônios/efeitos dos fármacos , Mapeamento de Peptídeos , Fosforilação , Cultura Primária de Células , Agregados Proteicos , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacologia , Células Sf9 , Spodoptera , Proteínas tau/genética , Proteínas tau/metabolismo , Proteínas tau/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA